5 Best Revenue Growth Stocks to Buy

4. Vir Biotechnology, Inc. (NASDAQ:VIR)

Number of Hedge Fund Investors In Q1 2023: 22

Vir Biotechnology, Inc. (NASDAQ:VIR) is a biotechnology firm that manufactures drugs and vaccines for immune system diseases, hepatitis, and influenza. With an average five year revenue growth rate of 538%, it is one of the fastest growing firms on our list. The firm’s shares are rated as a Strong Buy on average, with an average share price target of $49.71 – more than twice the current share price.

22 of the 943 hedge funds polled by Insider Monkey had held Vir Biotechnology, Inc. (NASDAQ:VIR)’s shares as of Q1 2023. Out of these, the largest investor is Steve Cohen’s Point72 Asset Management with an investment of $39 million.

Follow Vir Biotechnology Inc. (NASDAQ:VIR)